INDIANAPOLIS – Gov. Eric J. Holcomb joined Eli Lilly and Company Chair and CEO David A. Ricks on Wednesday to announce Lilly’s plans to increase its investment at the LEAP Research and Innovation District in Lebanon. The new $4.5 billion expansion brings Lilly’s total LEAP investment to more than $13 billion and enables Lilly to significantly increase its internal capacity to produce more innovative and next-generation therapies for clinical trials.
“Lilly’s continued investment in Indiana solidifies our state’s role as a hub for cutting-edge science and technology,” said Indiana Governor Eric J. Holcomb. “For nearly 150 years, Lilly has been committed to growing its roots and reach in Indiana, cultivating local talent, and driving scientific advancements that benefit patients around the world.”
The expansion includes the establishment of the Lilly Medicine Foundry (LMF) at the LEAP Research and Innovation District. This facility will be a new center for drug development and advanced manufacturing and will allow Lilly to develop and efficiently manufacture a wide range of molecular therapies, including small molecules, biologics, and nucleic acid therapies.
Since 2020, Lilly has committed more than $20 billion to build, expand, and acquire manufacturing facilities in the U.S. and Europe. In May 2022, Lilly first announced its plans to invest $2.1 billion and create up to 500 new jobs at LEAP. At the company’s Lebanon groundbreaking in April 2023, Lilly announced an additional $1.6 billion investment and 200 new jobs at the site. During the 2024 Indiana Global Economic Summit, Lilly announced an additional $5.3 billion expansion and 200 more jobs. Once completed, LMF is expected to add over 400 full-time jobs.
